Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Granese, Barbara ^a   Scala, Iris ^a   Spatuzza, Carmen ^a   Valentino, Anna ^a   Coletta, Marcella ^a   Vacca, Rosa Anna ^b   De Luca, Pasquale ^c   Andria, Generoso ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c Grande Ospedale Metropolitano   (Italy)

Author keywords

Down syndrome; Expression; NF kB; Trisomy 21; Ubiquitin proteasome system

Indexed keywords

CALCIUM; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC2; TRANSCRIPTION FACTOR RELA; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CELL NUCLEUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; DSCR1 GENE; DYRK1A GENE; ENZYME ACTIVITY; FETUS; FETUS CELL; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LYMPHOBLAST; LYMPHOBLASTOID CELL; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NFAT GENE; PATHOGENESIS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TRISOMY 21; UBIQUITINATION; VALIDATION STUDY;

CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 21; COMPUTATIONAL BIOLOGY; DOWN SYNDROME; DOWN-REGULATION; FIBROBLASTS; HUMANS; I-KAPPA B PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTES; MUSCLE PROTEINS; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTOR RELA; UBIQUITIN; UBIQUITINATION;

EID: 84879806462     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-24     Document Type: Article

References (112)

1. Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Amano K, Sago H, Uchikawa C, Suzuki T, Kotliarova SE, Nukina N, Epstein CJ, Yamakawa K, Hum Mol Genet 2004 13 1333 40 10.1093/hmg/ddh154 15138197
2. Gene expression from the aneuploid chromosome in a trisomy mouse model of Down syndrome. Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE, Genome Res 2004 14 1268 1274 10.1101/gr.2090904 15231743
3. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B, Saran NG, Pletcher MT, South ST, Stetten G, Lehrach H, Reeves RH, Yaspo ML, Genome Res 2004 14 1258 1267 10.1101/gr.1951304 15231742
4. The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Dauphinot L, Lyle R, Rivals I, Dang MT, Moldrich RX, Golfier G, Ettwiller L, Toyama K, Rossier J, Personnaz L, Antonarakis SE, Epstein CJ, Sinet PM, Potier MC, Hum Mol Genet 2005 14 373 384 15590701
5. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Mao R, Zielke CL, Zielke HR, Pevsner J, Genomics 2003 81 457 467 10.1016/S0888-7543(03)00035-1 12706104
6. Gene expression profile analysis in human T lymphocytes from patients with Down syndrome. Giannone S, Strippoli P, Vitale L, Casadei R, Canaider S, Lenzi L, D'Addabbo P, Frabetti F, Facchin F, Farina A, Carinci P, Zannotti M, Ann Hum Genet 2004 68 546 554 10.1046/j.1529-8817.2003.00123.x 15598213
7. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Mao R, Wang X, Spitznagel EL Jr, Frelin LP, Ting JC, Ding H, Kim JW, Ruczinski I, Downey TJ, Pevsner J, Genome Biol 2005 6 107 10.1186/gb-2005-6-13-r107 16420667
8. Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. Li CM, Guo M, Salas M, Schupf N, Silverman W, Zigman WB, Husain S, Warburton D, Thaker H, Tycko B, BMC Med Genet 2006 7 24 16539728
9. Specific transcriptional changes in human fetuses with autosomal trisomies. Altug-Teber O, Bonin M, Walter M, Mau-Holzmann UA, Dufke A, Stappert H, Tekesin I, Heilbronner H, Nieselt K, Riess O, Cytogenet Genome Res 2007 119 171 84 10.1159/000112058 18253026
10. Transcriptome analysis of human autosomal trisomy. FitzPatrick DR, Ramsay J, McGill NI, Shade M, Carothers AD, Hastie ND, Hum Mol Genet 2002 11 3249 56 10.1093/hmg/11.26.3249 12471051
11. Gene expression profile of trisomy 21 placentas: a potential approach for designing noninvasive techniques of prenatal diagnosis. Gross SJ, Ferreira JC, Morrow B, Dar P, Funke B, Khabele D, Merkatz I, Am J Obstet Gynecol 2002 187 457 462 10.1067/mob.2002.123542 12193943
12. Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. Tang Y, Schapiro MB, Franz DN, Patterson BJ, Hickey FJ, Schorry EK, Hopkin RJ, Wylie M, Narayan T, Glauser TA, Gilbert DL, Hershey AD, Sharp FR, Ann Neurol 2004 56 808 814 10.1002/ana.20291 15562430
13. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, Genesio R, D'Armiento M, Olla C, Paladini D, Zannini M, Nitsch L, BMC Genomics 2007 8 268 10.1186/1471-2164-8-268 17683628
14. Gene expression profiling in the adult Down syndrome brain. Lockstone HE, Harris LW, Swatton JE, Wayland MT, Holland AJ, Bahn S, Genomics 2007 90 647 60 10.1016/j.ygeno.2007.08.005 17950572
15. Genome-wide expression analysis of cultured trophoblast with trisomy 21 karyotype. Rozovski U, Jonish-Grossman A, Bar-Shira A, Ochshorn Y, Goldstein M, Yaron Y, Hum Reprod 2007 22 2538 45 10.1093/humrep/dem214 17635843
16. Genetics of quantitative variation in human gene expression. Cheung VG, Jen KY, Weber T, Morley M, Devlin JL, Ewens KG, Spielman RS, Cold Spring Harb Symp Quant Biol 2003 68 403 7 10.1101/sqb.2003.68.403 15338642
17. Genetic inheritance of gene expression in human cell lines. Monks SA, Leonardson A, Zhu H, Cundiff P, Pietrusiak P, Edwards S, Phillips JW, Sachs A, Schadt EE, Am J Hum Genet 2004 75 1094 105 10.1086/426461 15514893
18. Gene-expression variation within and among human populations. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM, Am J Hum Genet 2007 80 502 9 10.1086/512017 17273971
19. Genome-wide associations of gene expression variation in humans. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavaré S, Deloukas P, Dermitzakis ET, PLoS Genet 2005 1 78 10.1371/journal.pgen.0010078 16362079
20. Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes. Deutsch S, Lyle R, Dermitzakis ET, Attar H, Subrahmanyan L, Gehrig C, Parand L, Gagnebin M, Rougemont J, Jongeneel CV, Antonarakis SE, Hum Mol Genet 2005 14 3741 3749 10.1093/hmg/ddi404 16251198
21. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Prandini P, Deutsch S, Lyle R, Gagnebin M, Delucinge Vivier C, Delorenzi M, Gehrig C, Descombes P, Sherman S, Dagna Bricarelli F, Baldo C, Novelli A, Dallapiccola B, Antonarakis SE, Am J Hum Genet 2007 81 252 263 10.1086/519248 17668376
22. Gene expression variation in Down's syndrome mice allows prioritization of candidate genes. Sultan M, Piccini I, Balzereit D, Herwig R, Saran NG, Lehrach H, Reeves RH, Yaspo ML, Genome Biol 2007 8 91 10.1186/gb-2007-8-5-r91 17531092
23. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Aït Yahya-Graison E, Aubert J, Dauphinot L, Rivals I, Prieur M, Golfier G, Rossier J, Personnaz L, Creau N, Bléhaut H, Robin S, Delabar JM, Potier MC, Am J Hum Genet 2007 81 475 9 10.1086/520000 17701894
24. Identification of dysregulated genes in lymphocytes from children with Down syndrome. Sommer CA, Pavarino-Bertelli EC, Goloni-Bertollo EM, Henrique-Silva F, Genome 2008 51 19 29 10.1139/G07-100 18356936
25. Impairment of circulating endothelial progenitors in Down syndrome. Costa V, Sommese L, Casamassimi A, Colicchio R, Angelini C, Marchesano V, Milone L, Farzati B, Giovane A, Fiorito C, Rienzo M, Picardi M, Avallone B, Marco Corsi M, Sarubbi B, Calabrò R, Salvatore P, Ciccodicola A, Napoli C, BMC Med Genomics 2010 3 40 10.1186/1755-8794-3-40 20836844
26. A mouse embryonic stem cell bank for inducible overexpression of human chromosome 21 genes. De Cegli R, Romito A, Iacobacci S, Mao L, Lauria M, Fedele AO, Klose J, Borel C, Descombes P, Antonarakis SE, di Bernardo D, Banfi S, Ballabio A, Cobellis G, Genome Biol 2010 1 64
27. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Pérez-Jurado LA, Lehrach H, BMC Genomics 2011 12 229 10.1186/1471-2164-12-229 21569303
28. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR, Nature 2006 441 595 600 10.1038/nature04678 16554754
29. Overexpression of DSCR1 blocks zinc-induced neuronal cell death through the formation of nuclear aggregates. Lee EJ, Lee JY, Seo SR, Chung KC, Mol Cell Neurosci 2007 35 585 95 10.1016/j.mcn.2007.05.003 17596961
30. Down syndrome candidate region 1 increases the stability of the IkappaBalpha protein: implications for its anti-inflammatory effects. Kim YS, Cho KO, Lee HJ, Kim SY, Sato Y, Cho YJ, J Biol Chem 2006 281 39051 61 10.1074/jbc.M604659200 17062574
31. Dual-specificity tyrosine (Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, Kim MJ, Son MY, Seo H, Chung SH, Song WJ, J Neurochem 2008 104 1333 44 10.1111/j.1471-4159.2007.05075.x 18005339
32. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Canzonetta C, Mulligan C, Deutsch S, Ruf S, O'Doherty A, Lyle R, Borel C, Lin-Marq N, Delom F, Groet J, Schnappauf F, De Vita S, Averill S, Priestley JV, Martin JE, Shipley J, Denyer G, Epstein CJ, Fillat C, Estivill X, Tybulewicz VL, Fisher EM, Antonarakis SE, Nizetic D, Am J Hum Genet 2008 83 388 400 10.1016/j.ajhg.2008. 08.012 18771760
33. RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration. Porta S, Serra SA, Huch M, Valverde MA, Llorens F, Estivill X, Arbonés ML, Martí E, Hum Mol Genet 2007 16 1039 50 10.1093/hmg/ddm049 17341486
34. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Valenti D, Tullo A, Caratozzolo MF, Merafina RS, Scartezzini P, Marra E, Vacca RA, Biochem J 2010 431 299 310 10.1042/BJ20100581 20698827
35. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Valenti D, Manente GA, Moro L, Marra E, Vacca RA, Biochem J 2011 435 679 88 10.1042/BJ20101908 21338338
36. Impairment of methyl cycle affects mitochondrial methyl availability and glutathione level in Down's syndrome. Infantino V, Castegna A, Iacobazzi F, Spera I, Scala I, Andria G, Iacobazzi V, Mol Genet Metab 2011 102 378 82 10.1016/j.ymgme.2010.11.166 21195648
37. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Pallardó FV, Lloret A, Lebel M, Cogger VC, Le Couteur DG, Gadaleta MN, Castello G, Pagano G, d'Ischia M, Biogerontology 2010 11 401 419 10.1007/s10522-010-9269-4 20237955
38. BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients. Tlili A, Hoischen A, Ripoll C, Benabou E, Badel A, Ronan A, Touraine R, Grattau Y, Stora S, van Bon B, de Vries B, Menten B, Bockaert N, Gecz J, Antonarakis SE, Campion D, Potier MC, Bléhaut H, Delabar JM, Janel N, Mol Neurobiol 2012 46 297 303 10.1007/s12035-012-8284-7 22669612
39. Transcriptional response of lymphoblastoid cells to ionizing radiation. Jen KY, Cheung VG, Genome Res 2003 13 2092 100 10.1101/gr.1240103 12915489
40. Comparison of gene expression changes induced in mouse and human cells treated with direct-acting mutagens. Islaih M, Li B, Kadura IA, Reid-Hubbard JL, Deahl JT, Altizer JL, Watson DE, Newton RK, Environ Mol Mutagen 2004 44 401 19 10.1002/em.20065 15515172
41. Portrait of transcriptional responses to ultraviolet and ionizing radiation in human cells. Rieger KE, Chu G, Nucleic Acids Res 2004 32 4786 803 10.1093/nar/gkh783 15356296
42. Decreased expression of Hsp27 and Hsp70 in transformed lymphoblastoid cells from patients with spinocerebellar ataxia type 7. Tsai HF, Lin SJ, Li C, Hsieh M, Biochem Biophys Res Commun 2005 334 1279 86 10.1016/j.bbrc.2005.06.207 16039988
43. The impact of MECP2 mutations in the expression patterns of Rett syndrome patients. Ballestar E, Ropero S, Alaminos M, Armstrong J, Setien F, Agrelo R, Fraga MF, Herranz M, Avila S, Pineda M, Monros E, Esteller M, Hum Genet 2005 116 91 104 10.1007/s00439-004-1200-0 15549394
44. NF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1. Lee EJ, Seo SR, Um JW, Park J, Oh Y, Chung KC, J Biol Chem 2008 283 3392 400 18056702
45. Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. Liu H, Wang P, Song W, Sun X, FASEB J 2009 23 3383 92 10.1096/fj.09-134296 19509306
46. Steps Involved in Immortalization and Tumorigenesis in Human B-Lymphoblastoid Cell Lines Transformed by Epstein-Barr Virus. Sugimoto M, Tahara H, Ide S, Furuichi Y, Cancer Res 2004 64 3361 3364 10.1158/0008-5472.CAN- 04-0079 15150084
47. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T, Genes Dev 1995 9 1586 97 10.1101/gad.9.13.1586 7628694
48. Gene expression module discovery using gibbs sampling. Wu CJ, Fu Y, Murali TM, Kasif S, Genome Inform 2004 5 239 48
49. Gene expression informatics-it's all in your mine. Bassett DE Jr, Eisen MB, Boguski MS, Nat Genet 1999 1 Suppl 1 51 5
50. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA, Genome Biol 2003 4 3 10.1186/gb-2003-4-5-p3 12734009
51. GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. Zhang B, Schmoyer D, Kirov S, Snoddy J, BMC Bioinforma 2004 5 16 10.1186/1471-2105-5-16
52. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR, Science 2006 313 1929 35 10.1126/science.1132939 17008526
53. Probabilistic approach in activity prediction. Filimonov DA, Poroikov VV, Chemoinformatics Approaches to Virtual Screening Cambridge (UK): RSC Publishing, Alexandre V, Alexander T, 2008 182 216
54. Multi-targeted natural products evaluation based on biological activity prediction with PASS. Lagunin A, Filimonov D, Poroikov V, Curr Pharm Des 2010 16 1703 17 10.2174/138161210791164063 20222853
55. Guideline to reference gene selection for quantitative real-time PCR. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A, Biochem Biophys Res Commun 2004 313 856 62 10.1016/j.bbrc.2003.11.177 14706621
56. Comparison of 12 reference genes for normalization of gene expression levels in Epstein-Barr virus-transformed lymphoblastoid cell lines and fibroblasts. de Brouwer AP, van Bokhoven H, Kremer H, Mol Diagn Ther 2006 10 197 204 10.1007/BF03256458 16771605
57. Immunoblotting Methods for the Study of Protein Ubiquitination. Mimnaugh and Neckers, Posttranslational Modifications of Proteins: Tools for Functional Proteomics. Volume 194 Totowa, NJ: Humana Press Inc, Kannicht C, 2002 179 203
58. Accumulation of altered aspartyl residues in erythrocyte proteins from patients with Down's syndrome. Galletti P, De Bonis ML, Sorrentino A, Raimo M, D'Angelo S, Scala I, Andria G, D'Aniello A, Ingrosso D, Zappia V, FEBS J 2007 274 5263 77 10.1111/j.1742-4658.2007.06048.x 17892495
59. Utility of lymphoblastoid cell lines. Sie L, Loong S, Tan EK, J Neurosci Res 2009 87 1953 9 10.1002/jnr.22000 19224581
60. Growth rate from patient-derived lymphoblastoid cells with LRRK2 mutations. Tan EK, Sie L, Loong S, Mol Genet Metab 2008 95 113 10.1016/j.ymgme.2008.06.004 18657457
61. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. Lin CH, Tzen KY, Yu CY, Tai CH, Farrer MJ, Wu RM, J Biomed Sci 2008 5 661 666
62. Induction of amyloid precursor protein mRNA after heat shock in cultured human lymphoblastoid cells. Abe K, St George-Hyslop PH, Tanzi RE, Kogure K, Neurosci Lett 1991 125 169 171 10.1016/0304-3940(91)90019-P 1652710
63. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME, Cotman SL, J Biol Chem 2006 281 20483 93 10.1074/jbc.M602180200 16714284
64. Submicroscopic deletion in patients with Williams-Beuren syndrome influences expression levels of the nonhemizygous flanking genes. Merla G, Howald C, Henrichsen CN, Lyle R, Wyss C, Zabot MT, Antonarakis SE, Reymond A, Am J Hum Genet 2006 79 332 41 10.1086/506371 16826523
65. Genetic mechanisms involved in the phenotype of Down syndrome. Patterson D, Ment Retard Dev Disabil Res Rev 2007 13 199 206 10.1002/mrdd.20162 17910086
66. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Kim SH, Vlkolinsky R, Cairns N, Lubec G, Cell Mol Life Sci 2000 57 1810 6 10.1007/PL00000661 11130185
67. Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains. Kim SH, Fountoulakis M, Dierssen M, Lubec G, J Neural Transm Suppl 2001 61 109 16 11771736
68. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome. Lee SH, Lee S, Jun HS, Jeong HJ, Cha WT, Cho YS, Kim JH, Ku SY, Cha KY, Mol Cells 2003 15 181 5 12803480
69. Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down's syndrome cerebral cortex. Bajo M, Fruehauf J, Kim SH, Fountoulakis M, Lubec G, Proteomics 2002 2 1539 46 10.1002/1615-9861(200211)2:11<1539::AID- PROT1539>3.0.CO;2-C 12442254
70. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Druzhyna N, Nair RG, LeDoux SP, Wilson GL, Mutat Res 1998 409 81 9 10.1016/S0921-8777(98)00042-1 9838924
71. Mitochondrial dysfunction in mouse trisomy 16 brain. Bambrick LL, Fiskum G, Brain Res 2008 1188 9 16 18061151
72. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA, Neuron 2002 28 677 88
73. Mitochondria, oxygen free radicals, disease and ageing. Raha S, Robinson BH, Trends Biochem Sci 2000 25 502 8 10.1016/S0968-0004(00)01674-1 11050436
74. Neuronal degeneration and mitochondrial dysfunction. Schon EA, Manfredi G, J Clin Invest 2003 111 303 12 12569152
75. Delaying the mitochondrial decay of aging with acetylcarnitine. Ames BN, Liu, Ann N Y Acad Sci 2004 1033 108 116 10.1196/annals.1320.010 15591008
76. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Kidd PM, Altern Med Rev 2005 10 268 93 16366737
77. Molecular pathogenesis of Parkinson's disease. Gandhi S, Wood NW, Hum Mol Genet 2005 14 2749 2755 10.1093/hmg/ddi308 16278972
78. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW, Proc Natl Acad Sci USA 2009 106 9425 9 10.1073/pnas.0903909106 19474297
79. Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21. Costa V, Angelini C, D'Apice L, Mutarelli M, Casamassimi A, Sommese L, Gallo MA, Aprile M, Esposito R, Leone L, Donizetti A, Crispi S, Rienzo M, Sarubbi B, Calabrò R, Picardi M, Salvatore P, Infante T, De Berardinis P, Napoli C, Ciccodicola A, PLoS One 2011 6 18493 10.1371/journal.pone.0018493 21533138
80. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Ciechanover A, Cell Death Differ 2005 12 1178 90 10.1038/sj.cdd.4401692 16094394
81. Proteasome inhibition induces reversible impairments in protein synthesis. Ding Q, Dimayuga E, Markesbery WR, Keller JN, FASEB J 2006 20 1055 63 10.1096/fj.05-5495com 16770004
82. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype. Van Tijn P, Hol EM, van Leeuwen FW, Fischer DF, Prog Neurobiol 2008 85 176 93 10.1016/j.pneurobio.2008.03.001 18448229
83. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Huang Q, Figueiredo-Pereira ME, Apoptosis 2010 15 1292 311 10.1007/s10495-010-0466-z 20131003
84. The ubiquitin proteasome system in neuropathology. Lehman NL, Acta Neuropathol 2009 118 329 47 10.1007/s00401-009-0560-x 19597829
85. Review: the ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration. Rogers N, Paine S, Bedford L, Layfield R, Neuropathol Appl Neurobiol 2010 36 113 24 20202119
86. Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome. Engidawork E, Juranville JF, Fountoulakis M, Dierssen M, Lubec G, J Neural Transm Suppl 2001 61 117 30 11771738
87. Dysfunction of the ubiquitin-proteasome system in the cerebellum of aging Ts65Dn mice. Necchi D, Lomoio S, Scherini E, Exp Neurol 2011 232 114 8 10.1016/j.expneurol.2011.08.009 21867700
88. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndromemouse model. Choi JH, Berger JD, Mazzella MJ, Morales-Corraliza J, Cataldo AM, Nixon RA, Ginsberg SD, Levy E, Mathews PM, J Neurochem 2009 110 1818 27 10.1111/j.1471-4159.2009.06277.x 19619138
89. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Busciglio J, Yankner BA, Nature 1995 378 776 9 10.1038/378776a0 8524410
90. Oxidative stress and mitochondrial dysfunction in Down syndrome. Pagano G, Castello G, Adv Exp Med Biol 2012 724 291 9 10.1007/978-1-4614-0653-2-22 22411251
91. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Zana M, Janka Z, Kálmán J, Neurobiol Aging 2007 28 648 76 10.1016/j.neurobiolaging.2006.03.008 16624449
92. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. Peled-Kamar M, Lotem J, Okon E, Sachs L, Groner Y, EMBO J 1995 14 4985 93 7588627
93. The E3 ubiquitin ligase MIB1 negatively regulates basal IκBα level and modulates NF-κB activation. Liu LJ, Liu TT, Ran Y, Li Y, Zhang XD, Shu HB, Wang YY, Cell Res 2012 22 603 6 10.1038/cr.2011.199 22184009
94. Regulation of NF-κB by ubiquitination and degradation of the IκBs. Kanarek N, Ben-Neriah Y, Immunol Rev 2012 246 77 94 10.1111/j.1600-065X.2012.01098.x 22435548
95. Crosstalk in NF-κB signaling pathways. Oeckinghaus A, Hayden MS, Ghosh S, Nat Immunol 2011 12 695 708 21772278
96. Signaling through calcium, calcineurin, and NF-AT in lymphocyte activation and development. Stankunas K, Graef IA, Neilson JR, Park SH, Crabtree GR, Cold Spring Harb Symp Quant Biol 1999 64 505 16 10.1101/sqb.1999.64.505 11232327
97. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Beals CR, Clipstone NA, Ho SN, Crabtree GR, Genes Dev 1997 11 824 34 10.1101/gad.11.7.824 9106655
98. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Butterfield DA, Drake J, Pocernich C, Castegna A, Trends Mol Med 2001 7 548 54 10.1016/S1471-4914(01)02173-6 11733217
99. Beta-amyloid, oxidative stress and Down syndrome. Lott IT, Head E, Doran E, Busciglio J, Curr Alzheimer Res 2006 3 521 528 10.2174/156720506779025305 17168651
100. Clinical development of novel proteasome inhibitors for cancer treatment. Yang H, Zonder JA, Dou QP, Expert Opin Investig Drugs 2009 18 957 e971 10.1517/13543780903002074 19505187
101. Potential for proteasome inhibition in the treatment of cancer. Adams J, Drug Discov Today 2003 8 307 15 10.1016/S1359-6446(03)02647-3 12654543
102. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O, J Cancer Res Clin Oncol 2003 129 383 91 10.1007/s00432-003-0454-6 12851815
103. An essential role for NF-κB in preventing TNF-α-induced cell death. Beg AA, Baltimore D, Science 1996 274 782 784 10.1126/science.274.5288. 782 8864118
104. Suppression of TNF-α-induced apoptosis by NF-κB. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM, Science 1996 274 787 789 10.1126/science.274.5288.787 8864120
105. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Wang CY, Mayo MW, Baldwin AS, Science 1996 274 784 787 10.1126/science.274.5288.784 8864119
106. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Bogani P, Galli C, Villa M, Visioli F, Atherosclerosis 2007 190 181 6 10.1016/j.atherosclerosis.2006.01.011 16488419
107. Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Koh SH, Kwon H, Kim KS, Kim J, Kim MH, Yu HJ, Kim M, Lee KW, Do BR, Jung HK, Yang KW, Appel SH, Kim SH, Toxicology 2004 202 213 25 10.1016/j.tox.2004.05.008 15337584
108. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, Harbison RA, Linseman DA, Antioxid Redox Signal 2009 11 469 80 10.1089/ars.2008.2215 18754708
109. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. Nam S, Smith DM, Dou QP, J Biol Chem 2001 276 13322 30 10.1074/jbc.M004209200 11278274
110. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Khan N, Adhami VM, Mukhtar H, Endocr Relat Cancer 2010 17 39 52 10.1677/ERC-09-0262 19926708
111. The specificities of protein kinase inhibitors: an update. Bain J, McLauchlan H, Elliott M, Cohen P, Biochem J 2003 371 199 204 10.1042/BJ20021535 12534346
112. Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A. Guedj F, Sébrié C, Rivals I, Ledru A, Paly E, Bizot JC, Smith D, Rubin E, Gillet B, Arbones M, Delabar JM, PLoS One 2009 4 4606 10.1371/journal.pone.0004606 19242551